T-cell Developmental Status in Patients With Malignant Hematological Tumors

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

NCT04033302 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

NCT04480788 ·Status: UNKNOWN ·Phase: PHASE1

Study of 3D189 in Patients With Hematologic Malignancies

NCT05320809 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

NCT05388695 ·Status: RECRUITING ·Phase: PHASE1

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

NCT01694472 ·Status: UNKNOWN ·Phase: PHASE1

CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma

NCT05059912 ·Status: UNKNOWN ·Phase: PHASE2

Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

NCT03455972 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

NCT06633341 ·Status: RECRUITING ·Phase: EARLY_PHASE1

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

NCT06647329 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

NCT05420493 ·Status: RECRUITING ·Phase: PHASE1

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33

NCT01864902 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

NCT05620680 ·Status: RECRUITING ·Phase: NA

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

NCT05104775 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

NCT03994913 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

NCT04933825 ·Status: UNKNOWN ·Phase: NA

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

NCT04008394 ·Status: UNKNOWN ·Phase: PHASE1

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

NCT04440436 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

NCT03494179 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

NCT05290155 ·Status: COMPLETED ·Phase: PHASE1

A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

NCT04398953 ·Status: UNKNOWN ·Phase: PHASE2

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

NCT03720496 ·Status: UNKNOWN ·Phase: PHASE1

Safety and Efficacy Evaluation of CD19-UCART

NCT03229876 ·Status: SUSPENDED ·Phase: NA

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

NCT05326243 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

NCT06914037 ·Status: RECRUITING ·Phase: PHASE1

Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

NCT07106723 ·Status: RECRUITING ·Phase: PHASE2